Danaher (DHR) Stock Fundamentals, Analysis & Risk Signals

Health score, price, valuation, risk signals, and key metrics at a glance.

Danaher

NYSE•Healthcare•Diagnostics & Research

$212.50+4.14(0.02%)After hours

Market Cap

$149.48B

P/E

37.3x

P/S

6.0x

P/B

2.8x

Danaher Corporation designs, manufactures, and markets professional, medical, research, and industrial products and services in the United States, China, and internationally. The company operates through Biotechnology, Life Sciences, and Diagnostics segments. The Biotechnology segment provides technologies, consumables, services, and solutions that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, and aseptic fill finish; single-use hardware, consumables, and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services for diagnostic and assay development; and healthcare filtration solutions. The Life Sciences segment provides mass spectrometers; bioanalytical measurement systems; flow cytometry, genomics, lab automation, centrifugation, liquid handling automation instruments, antibodies and reagents, and particle counting and characterization; genome sample preparation; microscopes; protein consumables; filtration products; and genomic medicines, such as custom nucleic acid products, and plasmid DNA, RNA, and proteins under the ABCAM, ALDEVRON, BECKMAN COULTER, GENEDATA, IDT, LEICA MICROSYSTEMS, MOLECULAR DEVICES, PALL, PHENOMENEX, and SCIEX brands. The Diagnostics segment offers clinical instruments, consumables, software, and services that hospitals, physicians' offices, reference laboratories and other critical care settings use to diagnose disease and make treatment decisions. The company was formerly known as Diversified Mortgage Investors, Inc. and changed its name to Danaher Corporation in 1984. Danaher Corporation was incorporated in 1969 and is headquartered in Washington, the District Of Columbia.

How this company scores

GoodMetricSide Score: 73/100

Strongest: Cash & Earnings Quality (23/25); weakest: Balance Sheet & Red Flags (13/25).

Profitability18/25

Growth19/25

Balance Sheet & Red Flags13/25

Cash & Earnings Quality23/25

Strengths

Strong marginsRising earningsLow leverageCash-backed earnings

Valuation vs. 5-year range

Today's multiple positioned against its own trailing range — a visual premium/discount check.

P/E · 37.3x5y range 23.3x – 51.4x

Currently near its 20-quarter median.

P/S · 6.0x5y range 5.1x – 10.0x

Currently near its 20-quarter median.

P/B · 2.8x5y range 2.5x – 4.6x

Watch items

Data-driven signals worth keeping an eye on across the last 8 quarters

Some Concerns

Leverage Risk

Watch

Debt-to-equity has risen 48.5% recently — increasing financial risk even if the current ratio is manageable.

Price & Volume

Market Cap $149.48B

Metrics at a Glance

as of June 2026

Revenue & Profit

Revenue, EBITDA, operating income, net income, EPS, and shares

TTM Revenue: $25.11B
Q. Revenue: $6.26B
TTM EBITDA: $7.66B
TTM Op. Income: $5.13B
Q. Op. Income: $1.13B
TTM Net Income: $4.00B
Q. Net Income: $870.00M
EPS: $1.23
Shares Out.: $705.30M

$25.11B in TTM revenue grew 4.6% YoY, reaching $6.26B last quarter. TTM EBITDA of $7.66B and TTM operating income of $5.13B show growth is flowing through to the bottom line. TTM net income of $4.00B means revenue is converting into profit. Across the last 8 quarters, TTM revenue has risen for 5 consecutive quarters — an improving trend.

Margins

Gross, EBITDA, operating, and net margin trends

Gross Margin: 57.6%
EBITDA Margin: 28.5%
Op. Margin: 18.0%
Net Margin: 13.9%

Op. margin of 18.0% is up 5.2% YoY — cost efficiency is improving. Net margin at 13.9% and gross margin of 57.6% show how much of each revenue dollar survives to profit. Over the past year, operating margin is up 41% — a weakening trend.

Price Ratios

P/E, P/S, P/B, EV/EBITDA, FCF yield, and earnings yield

P/E Ratio: 37.3x
P/S Ratio: 6.0x
P/B Ratio: 2.8x

At 37.3x P/E, the stock trades above typical market levels — the market expects above-average growth. P/S of 6.0x and P/B of 2.8x provide additional context. P/E sits above typical market levels while revenue growth is below 5%. Over the past year, P/E is down 12% — a weakening trend.

Assets & Liabilities

Total assets, cash, debt, book value, and leverage

Total Assets: $92.37B
Cash: $4.35B
Long-Term Debt: $25.15B
Book Value: $52.58B
D/E Ratio: 0.5
Debt/EBITDA: 14.1

With $92.37B in assets and $25.15B in long-term debt, D/E is 0.5and book value is $52.58B — a conservative capital structure with a cushion to weather downturns. Over the past year, debt/equity is up 49% — a weakening trend.

Cash Flow

Operating cash flow, free cash flow, FCF margin, and earnings quality

Op. Cash Flow: $1.53B
TTM Free Cash Flow: $5.47B
FCF Margin: 21.8%
FCF / Net Income: 1.4

TTM FCF of $5.47B on $1.53B in operating cash flow. The FCF / Net Income ratio of 1.4x means free cash flow covers net income — earnings are backed by cash. Across the last 8 quarters, free cash flow has risen for 4 consecutive quarters — an improving trend.